Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection

Peter L. Anderson, Saleem E. Noormohamed, Keith Henry, Richard C. Brundage, Henry H. Balfour, Courtney V. Fletcher

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Study Objective. To characterize the concentration-time profiles of zidovudine and zidovudine-glucuronide in semen and serum of men infected with the human immunodeficiency-1 virus (HIV-1). Design. Open-label observational study. Setting. University-affiliated teaching hospital and research center. Patients. Four asymptomatic HIV-1-infected men. Interventions. Zidovudine administration was followed by an 8-hour intensive pharmacokinetic study on day 1. Over the next 8 days, a dose administration and timed single-sample strategy was employed to determine serum and semen concentration time profiles simultaneously. Measurements and Main Results. Zidovudine and zidovudine-glucuronide concentrations were uniformly higher in semen than in serum except at 1 hour after the dose. The median area under the curve ratio (semen AUC0-48: serum AUC(0-∞)) was 3.31 for zidovudine and 15.04 for zidovudine-glucuronide. Conclusion. Zidovudine and zidovudine-glucuronide reach high levels in seminal plasma relative to serum. The virologic, pharmacodynamic, and public health implications of distribution to this compartment require further study.

Original languageEnglish (US)
Pages (from-to)917-922
Number of pages6
JournalPharmacotherapy
Volume20
Issue number8I
DOIs
StatePublished - Jan 1 2000

Fingerprint

Zidovudine
Semen
HIV Infections
HIV-1
Pharmacokinetics
Serum
Area Under Curve
Teaching Hospitals
Observational Studies
Public Health
3'-azido-3'-deoxy-5'-O-beta-glucopyranuronosylthymidine
Research

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. / Anderson, Peter L.; Noormohamed, Saleem E.; Henry, Keith; Brundage, Richard C.; Balfour, Henry H.; Fletcher, Courtney V.

In: Pharmacotherapy, Vol. 20, No. 8I, 01.01.2000, p. 917-922.

Research output: Contribution to journalArticle

Anderson, Peter L. ; Noormohamed, Saleem E. ; Henry, Keith ; Brundage, Richard C. ; Balfour, Henry H. ; Fletcher, Courtney V. / Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. In: Pharmacotherapy. 2000 ; Vol. 20, No. 8I. pp. 917-922.
@article{376721a042264e3984fc5211e7004058,
title = "Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection",
abstract = "Study Objective. To characterize the concentration-time profiles of zidovudine and zidovudine-glucuronide in semen and serum of men infected with the human immunodeficiency-1 virus (HIV-1). Design. Open-label observational study. Setting. University-affiliated teaching hospital and research center. Patients. Four asymptomatic HIV-1-infected men. Interventions. Zidovudine administration was followed by an 8-hour intensive pharmacokinetic study on day 1. Over the next 8 days, a dose administration and timed single-sample strategy was employed to determine serum and semen concentration time profiles simultaneously. Measurements and Main Results. Zidovudine and zidovudine-glucuronide concentrations were uniformly higher in semen than in serum except at 1 hour after the dose. The median area under the curve ratio (semen AUC0-48: serum AUC(0-∞)) was 3.31 for zidovudine and 15.04 for zidovudine-glucuronide. Conclusion. Zidovudine and zidovudine-glucuronide reach high levels in seminal plasma relative to serum. The virologic, pharmacodynamic, and public health implications of distribution to this compartment require further study.",
author = "Anderson, {Peter L.} and Noormohamed, {Saleem E.} and Keith Henry and Brundage, {Richard C.} and Balfour, {Henry H.} and Fletcher, {Courtney V.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1592/phco.20.11.917.35263",
language = "English (US)",
volume = "20",
pages = "917--922",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "8I",

}

TY - JOUR

T1 - Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection

AU - Anderson, Peter L.

AU - Noormohamed, Saleem E.

AU - Henry, Keith

AU - Brundage, Richard C.

AU - Balfour, Henry H.

AU - Fletcher, Courtney V.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Study Objective. To characterize the concentration-time profiles of zidovudine and zidovudine-glucuronide in semen and serum of men infected with the human immunodeficiency-1 virus (HIV-1). Design. Open-label observational study. Setting. University-affiliated teaching hospital and research center. Patients. Four asymptomatic HIV-1-infected men. Interventions. Zidovudine administration was followed by an 8-hour intensive pharmacokinetic study on day 1. Over the next 8 days, a dose administration and timed single-sample strategy was employed to determine serum and semen concentration time profiles simultaneously. Measurements and Main Results. Zidovudine and zidovudine-glucuronide concentrations were uniformly higher in semen than in serum except at 1 hour after the dose. The median area under the curve ratio (semen AUC0-48: serum AUC(0-∞)) was 3.31 for zidovudine and 15.04 for zidovudine-glucuronide. Conclusion. Zidovudine and zidovudine-glucuronide reach high levels in seminal plasma relative to serum. The virologic, pharmacodynamic, and public health implications of distribution to this compartment require further study.

AB - Study Objective. To characterize the concentration-time profiles of zidovudine and zidovudine-glucuronide in semen and serum of men infected with the human immunodeficiency-1 virus (HIV-1). Design. Open-label observational study. Setting. University-affiliated teaching hospital and research center. Patients. Four asymptomatic HIV-1-infected men. Interventions. Zidovudine administration was followed by an 8-hour intensive pharmacokinetic study on day 1. Over the next 8 days, a dose administration and timed single-sample strategy was employed to determine serum and semen concentration time profiles simultaneously. Measurements and Main Results. Zidovudine and zidovudine-glucuronide concentrations were uniformly higher in semen than in serum except at 1 hour after the dose. The median area under the curve ratio (semen AUC0-48: serum AUC(0-∞)) was 3.31 for zidovudine and 15.04 for zidovudine-glucuronide. Conclusion. Zidovudine and zidovudine-glucuronide reach high levels in seminal plasma relative to serum. The virologic, pharmacodynamic, and public health implications of distribution to this compartment require further study.

UR - http://www.scopus.com/inward/record.url?scp=0033838988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033838988&partnerID=8YFLogxK

U2 - 10.1592/phco.20.11.917.35263

DO - 10.1592/phco.20.11.917.35263

M3 - Article

C2 - 10939552

AN - SCOPUS:0033838988

VL - 20

SP - 917

EP - 922

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 8I

ER -